Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Cardiovascular effects of sevelamer in stage 3 CKD.

Chue CD, Townend JN, Moody WE, Zehnder D, Wall NA, Harper L, Edwards NC, Steeds RP, Ferro CJ.

J Am Soc Nephrol. 2013 Apr;24(5):842-52. doi: 10.1681/ASN.2012070719. Epub 2013 Apr 18.

3.

Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure.

Maizel J, Six I, Dupont S, Secq E, Dehedin B, Barreto FC, Benchitrit J, Poirot S, Slama M, Tribouilloy C, Choukroun G, Mazière JC, Drueke TB, Massy ZA.

Kidney Int. 2013 Sep;84(3):491-500. doi: 10.1038/ki.2013.110. Epub 2013 Apr 17.

PMID:
23594676
4.
5.
6.

Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study.

Iimori S, Mori Y, Akita W, Takada S, Kuyama T, Ohnishi T, Shikuma S, Ishigami J, Tajima M, Asai T, Okado T, Kuwahara M, Sasaki S, Tsukamoto Y.

Clin Exp Nephrol. 2012 Dec;16(6):930-7. doi: 10.1007/s10157-012-0640-4. Epub 2012 May 12.

PMID:
22581064
7.

Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.

Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Mallamaci F, Zoccali C.

Am J Kidney Dis. 2012 Feb;59(2):177-85. doi: 10.1053/j.ajkd.2011.11.007. Epub 2011 Dec 2.

PMID:
22137672
8.

Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.

Chen N, Wu X, Ding X, Mei C, Fu P, Jiang G, Li X, Chen J, Liu B, La Y, Hou F, Ni Z, Fu J, Xing C, Yu X, Huang C, Zuo L, Wang L, Hunter J, Dillon M, Plone M, Neylan J.

Nephrol Dial Transplant. 2014 Jan;29(1):152-60. doi: 10.1093/ndt/gft232. Epub 2013 Oct 22.

PMID:
24151017
9.

Disturbances of Wnt/β-catenin pathway and energy metabolism in early CKD: effect of phosphate binders.

de Oliveira RB, Graciolli FG, dos Reis LM, Cancela AL, Cuppari L, Canziani ME, Carvalho AB, Jorgetti V, Moysés RM.

Nephrol Dial Transplant. 2013 Oct;28(10):2510-7. doi: 10.1093/ndt/gft234. Epub 2013 Aug 23.

PMID:
23975746
10.

Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial.

Wang AY, Fang F, Chan J, Wen YY, Qing S, Chan IH, Lo G, Lai KN, Lo WK, Lam CW, Yu CM.

J Am Soc Nephrol. 2014 Jan;25(1):175-86. doi: 10.1681/ASN.2013010103. Epub 2013 Sep 19.

11.

Sevelamer and CKD-associated cardiovascular disease: going further, but far from there.

Moysés RM, Canziani ME.

Kidney Int. 2013 Sep;84(3):429-31. doi: 10.1038/ki.2013.160.

PMID:
23989354
12.

Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.

Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF.

Am J Kidney Dis. 2009 Oct;54(4):619-37. doi: 10.1053/j.ajkd.2009.06.004. Epub 2009 Aug 18. Review.

PMID:
19692157
13.

Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease.

Seifert ME, de Las Fuentes L, Ginsberg C, Rothstein M, Dietzen DJ, Cheng SC, Ross W, Windus D, Dávila-Román VG, Hruska KA.

Am J Nephrol. 2014;39(5):392-9. doi: 10.1159/000362251. Epub 2014 May 6.

14.

Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients.

Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Vural A, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P.

Clin J Am Soc Nephrol. 2008 Jan;3(1):61-8. Epub 2007 Dec 5.

15.

Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis.

Tzanno-Martins C, Biavo BM, Ferreira-Filho O, Ribeiro-Junior E, João-Luiz MV, Degaspari S, Scavone C, Kawamoto E.

Int J Immunopathol Pharmacol. 2014 Jan-Mar;27(1):25-35.

PMID:
24674676
16.

Effects of phosphate binders in moderate CKD.

Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM.

J Am Soc Nephrol. 2012 Aug;23(8):1407-15. doi: 10.1681/ASN.2012030223. Epub 2012 Jul 19.

17.

Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients.

Lin HH, Liou HH, Wu MS, Lin CY, Huang CC.

Nephrology (Carlton). 2014 Nov;19(11):672-8. doi: 10.1111/nep.12319.

PMID:
25113414
18.

Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.

Hu P, Xuan Q, Hu B, Lu L, Wang J, Qin YH.

Int J Biol Sci. 2012;8(5):663-71. doi: 10.7150/ijbs.3886. Epub 2012 May 5. Review.

19.

A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study.

Covic A, Passlick-Deetjen J, Kroczak M, Büschges-Seraphin B, Ghenu A, Ponce P, Marzell B, de Francisco AL.

Nephrol Dial Transplant. 2013 Sep;28(9):2383-92. doi: 10.1093/ndt/gft203. Epub 2013 Jun 19.

20.

Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.

Perry CM, Plosker GL.

Drugs. 2014 May;74(7):771-92. doi: 10.1007/s40265-014-0215-7. Review.

PMID:
24811546

Supplemental Content

Support Center